Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W9LX
|
|||
| Former ID |
DAP000135
|
|||
| Drug Name |
Carvedilol
|
|||
| Synonyms |
Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Approved | [1], [2] | |
| Therapeutic Class |
Vasodilator Agents
|
|||
| Company |
GlaxoSmithKline plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H26N2O4
|
|||
| Canonical SMILES |
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
|
|||
| InChI |
1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
|
|||
| InChIKey |
OGHNVEJMJSYVRP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 72956-09-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9092, 7387304, 7847321, 7978866, 8151709, 11364559, 11367121, 11369683, 11372422, 11374391, 11377845, 11485621, 11489489, 11490997, 11492451, 11495479, 11528712, 12013067, 14855122, 26719722, 26719723, 29221745, 46386749, 46386871, 46505146, 47805057, 48415707, 49681735, 49834917, 50112972, 50112973, 53789407, 56313592, 56413047, 56464135, 57321386, 76450239, 81040900, 81092790, 85209910, 85789499, 85789708, 87560280, 90341342, 92251378, 92307922, 92308493, 92308705, 92711411, 103197484
|
|||
| ChEBI ID |
CHEBI:3441
|
|||
| ADReCS Drug ID | BADD_D00374 ; BADD_D00375 | |||
| SuperDrug ATC ID |
C07AG02
|
|||
| SuperDrug CAS ID |
cas=072956093
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides coprophilus DSM 18228
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides coprophilus DSM 18228 (log2FC = -1.653; p = 0.025). | |||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -1.225; p = 0.019). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -2.322; p = 0.027). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -1.632; p = 0.018). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -2.46; p = 0.014). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -2.656; p = 0.016). | |||
|
Studied Microbe: Bacteroides ovatus ATCC 8483
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides ovatus ATCC 8483 (log2FC = -1.243; p = 0.013). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -2.092; p = 0.012). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -1.683; p = 0.037). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -1.691; p = 0.034). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -1.426; p = 0.034). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Eubacterium biforme DSM 3989
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Eubacterium biforme DSM 3989 (log2FC = -1.604; p = 0.046). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Blautia hansenii DSM20583 (log2FC = -1.922; p = 0.01). | |||
|
Studied Microbe: Clostridium sporogenes ATCC 15579
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Clostridium sporogenes ATCC 15579 (log2FC = -2.566; p = 0.017). | |||
|
Studied Microbe: Roseburia intestinalis L1-82
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Carvedilol can be metabolized by Roseburia intestinalis L1-82 (log2FC = -0.975; p = 0.014). | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lactobacillus paracasei was decreased by Carvedilol (adjusted p-values: 4.25E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-1 (ADRA1) | Target Info | Antagonist | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 551). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.